1P53 over expression in skin lesions: An immunohistochemical study


  • Salah A. Omer Department of pathology, college of medicine, Hawler Medical University, Erbil, Iraq.
  • Yusra Abdulkhaliq Qasim Department of pathology, college of medicine, Hawler Medical University, Erbil, Iraq.
  • Jawhar Taher Omar Department of pathology, college of medicine, Hawler Medical University, Erbil, Iraq.




Immunohistochemistry, Tumor Suppressor gene (p53) protein and skin cancers


Background and objective: Immunohistochemistry is the application of immunologic principles and techniques to demonstrate molecules in cells and tissues. Gene p53 is a tumor-suppressor gene. The product of this gene is a nuclear protein thought to be involved in the control of the cell cycle, apoptosis, and the maintenance of genomic stability. Gene p53 is the most frequently mutated tumor suppressor gene found in human cancer. The aim of this study was to investigate p53 protein over expression in skin cancer and compare it with benign skin lesion.

Methods: A retrospective study was conducted on paraffin block from skin biopsy of 36 patients with various skin lesions; eight benign cases and 28 malignant cases. The sample of patients was collected from the Pathology Laboratory in Rizgary Teaching Hospital in Erbil, Kurdistan region, Iraq from December 2011 to December 2012. The age of the patients ranged from 34 to 80 years. The p53 protein over expression was investigated by immunohistochemical staining. Sample sections were stained and scored.

Results: Nineteen out of 28 (76.8%) skin cancer showed over expression of p53 gene compared with benign skin lesion and there was a statistically significant difference. There was statistical significant difference in relation to the age group of patients with various skin cancers which was higher in patient above 40 years.

Conclusion: Increased expression of p53 a nuclear protein can be detected in human skin cancer compared with benign skin lesion and it may play an important role in pathogenesis of many types of skin cancers.


Metrics Loading ...


Chan J KC. P53 expression. Rosai and Ackerman's Surgical Pathology. 10th Edition. New York, SA: Mosby Elsever; 2011. PP 58.

Purdie CA, Grady J, Piris J, Wylie AH, Biral. P53 expression in colorectal cancer. AJP 1991; 138 (4):22-7.

Ghaderi R, Haghighi F. Immunohistochemistry assessment of p53 protein in basal cell carcinoma. Iran J Allergy Asthma Immunol 2005; 4(4):167-71.

Kricker A, Armstrong B K, English DR, Heenan PJ. Pigmentary and cutaneous risk factors for nonmelanocytic skin cancer a case control study. Int J Cancer 1991; 48(5):650-62.

Marisa RN, Christopher PC. In Mills SE, Carter D, Greenson JK, Reuter VE and stoler MH, Editors. Sternberg. Non melanocytic cutaneous tumor. Diagnostic Surgical Pathology. 5th Edition. Baltimore USA: Lippinvott Williams and Wilkins; 2010. PP46-60.

Dinehart SM, Nelson-Adesokan P, Cockerell C, Russell S, Brown R. Metastatic cutaneous squamous cell carcinoma derived from actinic keratosis. Cancer 1997; 79(38):920-3.

Johnson TM, Rowe DE, Nelson BR, Swanson NA. Squamous cell carcinoma of the skin (excluding lip and oral mucosa).Journal American Acad Dermatol 1992; 26(5):467-84.

Agar NS, Halliday GM, Bametson RS .The basal layer in human squamous tumors harbors more UVA than UVB fingerprint mutations: A role for UVA in human skin carcinogenesis. Proc Natl Acad Sci USA 2004; 101(16):4954-9.

Shea CR, McNutt NS, Volkenandt M, Lugo J, Prioleau PG, Albino AP. Overexpression of p53 protein in basal cell carcinomas of human skin. Am J Pathol 1992; 141(1):25-9.

SoiniY, Kamel D,Pääkkö PLethtoV-P,Oikarinen A, VähäkangasK. Aberrant accumulation of p53 associates with Ki67 and mitotic count in benign skin lesions. British J Dermatol 1994; 131(4): 514-20.

Brown DC, Gatter KC. Ki67 protein: The immaculate deception? Histopathol 2002; 40(1): 2-11.

Shimuzu T, Oga A, Murakami T, Muto M. Overexpression of p53 protein associated with proliferative activity and histological degree of malignancy in solar keratosis. Dermatol 1999; 28(6):113-8.

Hermeking H, Eick D. Mediation of c-Myc-induced apoptosis by p53. Science 1994; (26)5:2091-3.

Shimuitzu T, Muto M, Murakami T, Furumoto H, Mogami S, Asagami C. Over expression of p53 protein associated with proliterative activity as evaluated by Ki-67 immunostaining in well-differentiated squamous cell carcinoma of the skin. Dermatol 1997; 195(3):224-7.

Ringer DP, Schniper LE. Principles of cancer biology. Gene mutation that can lead to cancer. In: Lenhard RE, Osteen RT, Gansler T. Clinical Oncology. Atlanta, GA: American Cancer Society; 2001: 25– National Cancer Institute. Understanding Gene Testing. Accessed at http://www.cancer.gov/cancertopics/understandingcancer/genetesting on 12/13/2011.

Sidransky D, Hollstein M. Clinical implications of the p53 Gene. Annu Rev Med 1996; 47(3): 285-301.

Whiteman DC, Parsons PG, Green AC. p53 expression and risk factors for cutanous melanoma: A case control-study. Int J Cancer 1998; 77(6):843-8.

Jonason AS1, Kunala S, Price GJ, Restifo RJ, Spinelli HM, Persing JA, et al. Frequent clones of p53-mutated keratinocytes in normal human skin. Proc Natl Acad Sci USA 1996; 93(24):14025-9.

Batinac PT, Zamolo G, Jonjic N, Gruber F, Petroveckj M. P53 protein expression and cell proliferation in non neoplastic and neoplastic proliferative skin diseases. Tumori 2004; 90(6):120-7.

Ouhtit A, Nakazawa H, Yamasaki H, Armstrong BK, Kricker A, Tan E, et al. UV-radiation-specific p53 mutation frequency in normal skin as a predictor of risk of basal cell carcinoma. J Natl Cancer Inst 1998; 90(7):523-31.




How to Cite

Omer, S. A., Qasim, Y. A., & Omar, J. T. (2015). 1P53 over expression in skin lesions: An immunohistochemical study. Zanco Journal of Medical Sciences (Zanco J Med Sci), 19(3), 1091 _ 1095. https://doi.org/10.15218/zjms.2015.0037



Original Articles